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havWe are proud to present this special issue of Value in Health:
Pharmacoeconomics and Outcomes Research in Latin America. We
resent a combination of plenary summaries presented at the
nternational Society of Pharmacoeconomics and Outcomes Re-
earch (ISPOR) Second Latin America Conference held in Brazil
uring September 2009, and original research studies con-
ucted in our region. We think this corpus gives a very rich
icture of the current state of pharmacoeconomics and out-
omes research in Latin America.
Like the ISPOR Asia Consortium [1,2], the ISPOR Latin Amer-
ca Consortium promotes biennial conferences held in the re-
ion with a two-fold mission: to help develop knowledge and
apacity for health economics and outcomes research in Latin
merica and to promote the use of health economics and out-
omes research in policy-making processes, with the goal of
mproving resource allocation efficiency. This second ISPOR
atin American conference, with its theme “Uniting Research
nd Policy to Improve Health Care in Latin America,” had a
ajor level of participation and success in the region.
During the past decade or so, a large number of Latin Amer-
can countries have undertaken profound reforms of their
ealth care systems. Even though the details are country-spe-
ific, a common issue is the need to establish a mechanism that
nsures efficient allocation of scarce resources, as well as guar-
nteeing a wide provision of health care services on the basis of
ocal population needs and equity [3].
We are currently witnessing the adolescence of the health
conomics and outcomes research field in Latin America after
eaching some relevant regional milestones, namely the estab-
ishing of the Latin American branch of the International Clin-
cal Epidemiology Network during the 1980s, development of
he Thematic Network on the Economic Evaluation of Health
rogrammes in Latin America (NEVALAT) in the early 2000s, the
rowth of the Cochrane Collaboration, the creation of several
ealth technology assessment agencies in the region affiliated
ith the International Network of Agencies for Health Technol-
gy Assessment around 2005, as well as the creation of the IS-
OR Latin America Consortium and local country chapters act-
ng from 2006 on. In addition, regional common country
lliances like MERCOSUR and the Andean Community are also
dvancing in harmonizing health technology assessment and
conomic evaluations in their member countries.
It has been a great learning experience to be the editors of
his special issue, the review process of which adheres to cur-
ent standards for international scientific journals. Both the
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article.rocess and the results reflect the challenges of a region like
atin America, which is in the early phases of strengthening the
ealth economics and outcomes research field [3]. Barriers in-
lude the scarcity of good and methodologically sound ques-
ions, difficulty in using state-of-the-art methods and tools,
aucity of local primary data and therefore reliance on interna-
ional data in the field of modeling studies, and a limited dis-
ussion of applicability of results to inform and influence deci-
ions [4]. A recent study [3] concluded that to promote the use of
economic evaluation in this region, two main conditions need
to be fulfilled: 1) adequate resources and skills need to be avail-
able; and 2), decision-making process needs to be modified to
accommodate evidence-based approaches such as economic
evaluations [3].
From the 57 submissions we received, 30 articles were ac-
cepted for final publication in the current issue. We have repre-
sentation from six countries, and the topics range from eco-
nomic analysis (53%), to health outcomes analysis (40%) and
health policy analysis (7%). Though all abstracts are in English,
we decided to publish not only studies written in English (50%)
but also in Spanish (40%) and in Portuguese (10%), because these
are the twomain languages used in Latin America. Amajority of
the issue reviewers were from Latin America (64%), which also
shows the growth of interest in the field. Reviews were usually
heterogeneous and sometimes discordant, and we made a large
effort to try to reconcile them as much as possible.
We are a part of the first attempt to publish a special issue of
original research in the field conducted in Latin America, with
plenty of examples of studies in this growing discipline. We are
aware that this is an evolving field in our region, and that most
of our production does not satisfy the most rigorous interna-
tional standards (i.e., descriptive studies of a highly selected
population, economic evaluation with scarcity of good quality
local data inputs, small sample size, basic analytical ap-
proaches in observational studies, or modeling techniques in
economic evaluations). Nevertheless, we think the glass is half
full, with many regional efforts reflected.
We hope you enjoy what to our knowledge is a mile-
stone that reflects the current state of the art of the health
economics and outcomes research field in Latin America. It is
our desire that it can act as a stimulus to our community to
strengthen our capacities and standards to contribute to evi-
dence-based resource allocation decisions in this rapidly grow-
ing region.
e no conflicts of interest with regard to the content of this
S2 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 1 – S 2Federico Augustovski, MD, MSc, PhD
Director, Departamento de Evaluaciones Económicas y de
Tecnologías Sanitarias/Economic Evaluations and Heath
Technology Assessment Department, Instituto de Efectividad
Clínica y Sanitaria/Institute for Clinical Effectiveness and Health
Policy; and profesor de Salud Pública/Professor of Public Health,
Universidad de Buenos Aires, Servicio de Medicina Familiar y
Comunitaria/Family and Community Medicine Division, Hospital
Italiano de Buenos Aires, Argentina.
Marcos Bosi Ferraz, MD, PhD
Department of Medicine, Federal University of São Paulo; Center
for Health Economics, São Paulo, Brazil; and Medical Economics of
the Brazilian Medical Association, São Paulo, Brazil.
1098-3015/$36.00 – see front matter
Copyright © 2011, International Society forPharmacoeconomics and Outcomes Research (ISPOR).Published by Elsevier Inc.
doi:10.1016/j.jval.2011.06.001
R E F E R E N C E S
[1] Yang BM, Lee K. Growing application of pharmacoeconomics and
outcomes research in health-care decision-making in the Asia-Pacific
region. Value Health 2009;12(Suppl. 3):S1–2.
[2] Liu GG, Eggleston K, Hu TW. Emerging health economics and outcomes
research in the Asia-Pacific region. Value Health 2008;11(Suppl. 1):S1–2.
[3] Iglesias CP, Drummond MF, Rovira J; NEVALAT Project Group.Health-
care decision-making processes in Latin America: problems and
prospects for the use of economic evaluation. Int J Technol Assess
Health Care 2005;21:1–14.
[4] Augustovski F, Iglesias C, Manca A, et al. Barriers to generalizability of
health economic evaluations in Latin America and the Caribbean
region. Pharmacoeconomics 2009;27:919–29.
